Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter

MT Newswires Live

2025/10/31

Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.

It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.

It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.

Its shares fell 2% in recent trading on Friday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2579848629"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2579848629\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2579848629?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579848629","market":"sg","top_or_hot":-1,"title":"Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Race Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRace Oncology Advanced Phase One Cardioprotection, Anti-Cancer Drug Candidate Clinical Trial in the September Quarter\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-10-31 09:49</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RAC.AU\">Race Oncology</a> (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.</p><p>It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.</p><p>It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.</p><p>Its shares fell 2% in recent trading on Friday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAC.AU","symbol_name":"RACE ONCOLOGY LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2579848629","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579848629","pubTimestamp":1761875382,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Race Oncology  said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAC.AU":"RACE ONCOLOGY LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Race Oncology高级一期心脏保护、抗癌候选药物临床试验将于9月季度进行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAC.AU":1},"content_text":"Race Oncology (ASX:RAC) said it continued to progress the phase one cardioprotection and anti-cancer clinical trial of its RC220 drug candidate in combination with doxorubicin, or RAC-010, during the September quarter, according to a Friday Australian bourse filing.It said patients had been safely treated with RC220 as a single agent and in combination with doxorubicin, and additional sites in Hong Kong and South Korea received ethics and regulatory approval. Increased patient recruitment is expected in the December quarter with the activation of five additional sites in Hong Kong and South Korea.It filed three patents protecting the composition, manufacture, formulation, and use of the active (E,E)-bisantrene drug candidate, which will also allow for the advancement of the acute myeloid leukaemia-focused RC110 formulation into a pivotal phase three trial.Its shares fell 2% in recent trading on Friday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}